Title Dijagnostička vrijednost serumske koncentracije kemokina CXCL13 u bolesnika s karcinomom prostate Title (english) Diagnostic value of serum chemokine CXCL13 concentration in patients with prostate cancer Author Marjan Marić Mentor Željko Kaštelan (mentor)Committee member Borislav Spajić (predsjednik povjerenstva)Committee member Mario Štefanović (član povjerenstva)Committee member Stela Bulimbašić (član povjerenstva)Granter University of Zagreb Defense date and country 2022-12-19, Croatia Scientific / art field, BIOMEDICINE AND HEALTHCARE Universal decimal classificationUDC ) 616 - Pathology. Clinical medicine Abstract Cilj našeg istraživanja je bio utvrditi visinu serumske koncentracije kemokina CXCL13 i njenu dijagnostičku vrijednost u bolesnika s KP. U istraživanje su bili uključeni muškarci kojima je vodeći urolog na osnovu povišenih vrijednosti PSA i/ili sumnjivog nalaza DRP indicirao biopsiju prostate. Istraživanje je osmišljeno kao prospektivna opservacijska studija, ukupno je uključen 161 ispitanik. Ispitanici su podijeljeni u dvije skupine, oni kojima je biopsijom dokazan KP (86 ispitanika) te oni kojima u bioptatu prostate nije dokazan karcinom (75 ispitanika). Kriterij za isključenje iz studije su bili akutna infektivna bolest, autoimuna bolest te drugi malignom. Sve biopsije su učinjene koristeći transrektalnu ultrazvučnu sondu nakon primjene lokalnog anestetika što je u vrijeme provođenja studije bio zlatni standard. Od svih ispitanika je venepunkcijom na dan biopsije prostate uzeto 5 ml seruma radi dokaza kemokina. Navedeni uzorci su spremljeni na -20oC tijekom predviđenog vremena trajanja studije. Bioptati prostatičnog tkiva su pohranjeni u formalin te poslani u Zavod za patologiju Kliničkog Bolničkog Centra Zagreb radi patohistološke analize. Za određivanje koncentracije serumskog PSA korišten je Alinity i® test (Abbott Laboratories, IL, USA) dok je serumski CXCL13 određivan pomoću standardiziranih kvantitativnih enzimskih imunotestovia Quantikine Human CXCL10/IP-10 ELISA test, Quantikine Human CXCL11/I-TAC ELISA test i Quantikine Human CXCL13/ BLC/BCA-1 ELISA test (R&D Systems, Minneapolis, SAD).
Naša studija je potvrdila od ranije poznatu činjenicu da su serumske vrijednosti PSA kod ispitanika sa dokazanim KP više u odnosu na one kojima biopsijom nije dokazana maligna bolest prostate. Za razliku od drugih studija koje su pokazale da je CXCL13 značajno povišen u serumu pacijenata s KP, da pozitivno korelira sa serumskim PSA te da je čak i bolji prediktor agresivnije forme KP od PSA, naša studija nije uspjela potvrditi moguću korisnost serumskih razina CXCL13 za selekciju pacijenata za biopsiju prostate. Moguće je da bi studija na većem broju ispitanika koji bi uključivala i veći raspon kliničkih stadija, odnosno patohistoloških nalaza s obzirom na GZ, potvrdila ulogu kemokina CXCL13, zbog toga su potrebna daljnja istraživanja kemokina CXCL13 kod bolesnika s KP. Zbog nedovoljne osjetljivosti i specifičnosti PSA kao dosadašnjeg „zlatnog standarda“ u dijagnostici KP potrebne su nove molekule, odnosno novi biomarkeri koji bi bolje usmjeravali dijagnostiku, obradu i liječenje bolesnika s KP.
Abstract (english) The aim of our study was to determine the level of serum chemokine CXCL13 concentration and its diagnostic value in patients with PCa. The study included men who had a prostate biopsy based on elevated PSA and/or a suspicious DRE finding. The study was designed as a prospective observational study, with a total of 161 subjects included. Subjects were divided into two groups, those whose biopsy showed PCa (86 subjects) and those whose prostate biopsy did not show cancer (75 subjects). Criteria for exclusion from the studies were acute infectious disease, autoimmune disease and other malignancies. All biopsies were performed using a transrectal ultrasound probe after administration of a local anesthetic which was the gold standard at the time of the study. Of all subjects, 5 ml of serum was taken by venipuncture on the day of prostate biopsy for chemokine measurment. Alinity i® test (Abbott Laboratories, IL, USA) was used to determine serum PSA concentrations, while serum CXCL13 was determined using standardized quantitative enzyme immunoassays Quantikine Human CXCL10 / IP-10 ELISA test, Quantikine Human CXCL11 / Id CACn test BLC / BCA-1 ELISA test (R&D Systems, Minneapolis, USA). Our study confirmed the previously known fact that the serum PSA values in subjects with proven PCa are higher than those in whom biopsy did not prove malignant prostate disease. Unlike other studies that showed that CXCL13 was significantly increased in the serum of patients with PCa, positively correlated with serum PSA, and that it was an even better predictor of more aggressive forms of PCa than PSA, our study failed to confirm the potential utility of serum CXCL13 levels for selection of patients for prostate biopsy. It is possible that a study with a larger number of subjects, which would include a wider range of clinical stages, ie pathohistological findings with respect to GS, would confirm the role of chemokine CXCL13, therefore further research on chemokine CXCL13 in patients with PCa is needed. Due to the insufficient sensitivity and specificity of PSA as the current "gold standard" in the diagnosis of PCa, new molecules are needed, ie new biomarkers that would better guide the diagnosis and treatment of patients with KP.
Keywords
Prostata
Antigen specifičan za prostatu
Kemokin CXCL10
Flebotomija
Biopsija
Bolesti prostate
Autoimune bolesti
Zarazne bolesti
Imunotest
Keywords (english)
Prostate
Prostate-Specific Antigen
Chemokine CXCL10
Phlebotomy
Biopsy
Prostatic Diseases
Autoimmune Diseases
Communicable Diseases
Immunoassay
Language croatian URN:NBN urn:nbn:hr:105:008514 Study programme Title: Biomedicine and Health Sciences Type of resource Text Extent 69 str. File origin Born digital Access conditions Open access Terms of use Created on 2023-01-12 08:46:34
